Triana Paloma, Sarmiento María Del Carmen, Rodriguez-Laguna Lara, Martinez-Glez Victor, Lopez-Gutierrez Juan Carlos
Pediatric surgery, La Paz Children's Hospital, Madrid, Spain.
Pediatric surgery, La Paz Children's Hospital, Madrid, Spain.
Ann Vasc Surg. 2023 Jan;88:233-238. doi: 10.1016/j.avsg.2022.06.097. Epub 2022 Jul 22.
PIK3CA-related overgrowth syndrome (PROS) include a heterogeneous group of disorders characterized by segmental overgrowth secondary to somatic mosaic activating variants in PIK3CA. Segmental undergrowth is more uncommon and has been less studied but pathogenic variants in PIK3CA have also been found. With this in mind, we have noticed a group of patients with PROS that present an undergrowth component associated with their focal overgrowth.
Retrospective review of patients with PROS presenting overgrowth of the lower limb and undergrowth of the ipsilateral first toe was performed.
Six patients were included, 4 female and 2 male with a median age of 16.8 years. All patients presented a PROS phenotype with overgrowth of the lower limb and undergrowth of ipsilateral first toe. A PIK3CA pathogenic variant was confirmed in all patients. Patients underwent multiple treatments, currently all are receiving alpelisib with a mean duration of 15.8 months (1-39) and partial response in lipomatosis and vascular anomalies but no response in overgrowth and undergrowth so far.
Pathogenic variants in the same gene can create different phenotypes depending on the time and place of the mutation. There is little information regarding opposing phenotpyes in the same patient with PROS. The presence of undergrowth in our series might be explained by genetic, embryogenic, maternal, or placental factors but needs to be further investigated.
PIK3CA相关过度生长综合征(PROS)包括一组异质性疾病,其特征是由于PIK3CA体细胞镶嵌激活变异导致节段性过度生长。节段性生长不足较为罕见,研究较少,但也发现了PIK3CA的致病变异。考虑到这一点,我们注意到一组PROS患者,其局部过度生长伴有生长不足成分。
对表现为下肢过度生长和同侧第一趾生长不足的PROS患者进行回顾性研究。
纳入6例患者,4例女性,2例男性,中位年龄16.8岁。所有患者均表现出PROS表型,即下肢过度生长和同侧第一趾生长不足。所有患者均确诊存在PIK3CA致病变异。患者接受了多种治疗,目前所有患者均在接受阿培利司治疗,平均疗程15.8个月(1 - 39个月),脂肪瘤和血管异常有部分缓解,但目前过度生长和生长不足无缓解。
同一基因的致病变异可根据突变的时间和位置产生不同的表型。关于PROS同一患者出现相反表型的信息很少。我们系列研究中生长不足的存在可能由遗传、胚胎发育、母体或胎盘因素解释,但需要进一步研究。